Loading...
XSHE300298
Market cap1.72bUSD
Jan 15, Last price  
22.74CNY
1D
-2.57%
1Q
-17.49%
Jan 2017
80.52%
IPO
257.07%
Name

Sinocare Inc

Chart & Performance

D1W1MN
XSHE:300298 chart
P/E
44.28
P/S
3.10
EPS
0.51
Div Yield, %
0.88%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
21.22%
Revenues
4.06b
+44.26%
35,304,30069,531,166160,231,263209,473,957339,120,844449,053,363544,923,196645,500,737795,841,2521,033,007,6601,550,513,3741,778,209,2522,015,214,1062,361,308,0582,813,500,9944,058,786,045
Net income
284m
-36.31%
7,167,74526,074,02954,858,76088,161,354128,826,147165,306,276197,339,208143,662,991115,198,311257,971,916310,448,363250,683,386186,890,338107,569,179446,506,558284,397,911
CFO
735m
+54.97%
7,627,59643,025,80667,083,28385,932,932129,120,619114,416,407153,148,887121,519,206203,417,116243,891,125319,265,971522,807,472504,641,320480,028,164474,386,562735,145,903
Dividend
Jun 17, 20240.2 CNY/sh
Earnings
May 21, 2025

Profile

Sinocare Inc. engages in the development, manufacture, and marketing of diagnosis rapid testing products primarily in the People's Republic of China. It offers SARS-CoV-2 antibody test strip; Safe-Accu blood glucose monitoring systems; Safe-AQ blood glucose monitoring systems; Gold-Accu blood glucose monitoring systems; Safe-Accu UG blood, glucose, and uric acid monitoring systems; Safe-Accu KG blood, glucose, and ketone monitoring systems; and D Nurse mobile glucose meters. The company provides its products for the patients with chronic diseases and diabetes, as well as for healthcare professionals. It also exports its products to 135 countries. Sinocare Inc. was founded in 2002 and is based in Changsha, the People's Republic of China.
URL
https://www.sinocare.com/
IPO date
Mar 19, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,058,786
44.26%
2,813,501
19.15%
Cost of revenue
2,985,325
2,223,604
Unusual Expense (Income)
NOPBT
1,073,461
589,897
NOPBT Margin
26.45%
20.97%
Operating Taxes
52,716
42,036
Tax Rate
4.91%
7.13%
NOPAT
1,020,745
547,861
Net income
284,398
-36.31%
446,507
315.09%
Dividends
(111,453)
(111,554)
Dividend yield
0.66%
0.59%
Proceeds from repurchase of equity
(34,192)
BB yield
0.20%
Debt
Debt current
170,317
49,956
Long-term debt
912,199
483,669
Deferred revenue
124,094
124,501
Other long-term liabilities
99,007
10,464
Net debt
(79,807)
(309,907)
Cash flow
Cash from operating activities
735,146
474,387
CAPEX
(346,604)
Cash from investing activities
Cash from financing activities
(406,210)
FCF
388,455
306,773
Balance
Cash
816,038
843,533
Long term investments
346,285
Excess cash
959,384
702,858
Stockholders' equity
1,876,459
1,918,836
Invested Capital
3,797,148
3,055,953
ROIC
29.79%
21.13%
ROCE
22.37%
15.57%
EV
Common stock shares outstanding
556,879
558,211
Price
30.40
-9.87%
33.73
12.77%
Market cap
16,929,110
-10.09%
18,828,463
12.13%
EV
17,241,375
18,540,340
EBITDA
1,284,602
703,050
EV/EBITDA
13.42
26.37
Interest
66,285
20,663
Interest/NOPBT
6.17%
3.50%